ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology’s common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight’s inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock option has an exercise price of $1.68 per share, which is equ
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Appoints Jeff Knight as Chief Development and Operating OfficerGlobeNewswire
- ALX Oncology (ALXO) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $5.00 price target on the stock.MarketBeat
- ALX Oncology (ALXO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- ALX Oncology initiated with a Buy at UBS [Yahoo! Finance]Yahoo! Finance
ALXO
Earnings
- 2/27/26 - Miss
ALXO
Sec Filings
- 4/17/26 - Form 4
- 4/17/26 - Form 4
- 4/17/26 - Form 3
- ALXO's page on the SEC website